AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.

Create a link to this page

Copy and paste this link tag into your Web page or blog:

<a href="http://www.accessmylibrary.com/article-1G1-82623509/press-release-bristol-myers.html" title="Facts and information about Press Release: Bristol-Myers Squibb and Otsuka Pharmaceutical Co Ltd announce Marketing Authorization Application submission for aripiprazole.">Press Release: Bristol-Myers Squibb and Otsuka Pharmaceutical Co Ltd announce Marketing Authorization Application submission for aripiprazole.</a>

Close Set up an RSS feed that alerts you when new articles from Chemical Business Newsbase are available.

Frequently asked questions about RSS feeds

Press Release: Bristol-Myers Squibb and Otsuka Pharmaceutical Co Ltd announce Marketing Authorization Application submission for aripiprazole.

Chemical Business Newsbase

| December 17, 2001 | COPYRIGHT 2000 Elsevier Engineering Information, Inc. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)Copyright

Bristol-Myers Squibb Co and Otsuka Pharmaceutical Co Ltd announced the submission of a Marketing Authorization Application to the European Medicines Evaluation Agency for aripiprazole, an investigational novel drug for the treatment of schizophrenia. The filing, submitted on 5 Dec 2001 is based on an extensive global clinical development programme for aripiprazole, involving several controlled trials of up to 52 weeks in duration involving more than 3400 patients with schizophrenia. Bristol-Myers Squibb and Otsuka Pharmaceutical submitted a New Drug Application for aripiprazole with the US Food and Drug …

View articles courtesy of your local library

Related articles from newspapers, magazines, journals, and more


Bristol-Myers Squibb and Otsuka Pharmaceutical Co., Ltd. Submit New Drug...: Press release article from: PR Newswire November 7, 2001 700+ words
...these data, Bristol-Myers Squibb and Otsuka Pharmaceutical also expect to file...About Bristol-Myers Squibb and Otsuka Pharmaceutical Co., Ltd. Bristol-Myers Squibb Company and Otsuka Pharmaceutical Co., Ltd., are...


Bristol-Myers Squibb and Otsuka Pharmaceutical Co., Ltd. Announce Exclusive...: Press release article from: PR Newswire December 27, 2006 700+ words
...FirstCall/ -- Bristol-Myers Squibb Company and Otsuka Pharmaceutical Co., Ltd. today...About Bristol-Myers Squibb Bristol-Myers Squibb is a global pharmaceutical...human life. About Otsuka Pharmaceutical Co., Ltd. Founded...


PRESS RELEASE: Bristol-Myers Squibb and Otsuka Pharmaceutical Co Ltd submit New...: News wire article from: Chemical Business Newsbase November 15, 2001 700+ words
...Bristol-Myers Squibb Co and Otsuka Pharmaceutical Co Ltd announced...Bristol-Myers Squibb Co and Otsuka pharmaceutical Co Ltd...countries. Otsuka Pharmaceutical Co Ltd is...Bristol-Myers Squibb Co is a...


Bristol-Myers Squibb and Otsuka Pharmaceutical Spend Nearly Twice as Much on...: Press release article from: PR Newswire March 5, 2008 700+ words
...a new report that finds that Bristol-Myers Squibb and Otsuka Pharmaceutical spend almost twice as much on Abilify...and fewer than 10% mention Bristol- Myers Squibb or Otsuka Pharmaceutical as a top-of-mind company in atypical...


Bristol-Myers Squibb Co and Otsuka Pharmaceutical Co Ltd announce availability...: News wire article from: Chemical Business Newsbase February 7, 2006 700+ words
...NewsBase - Press Release) Bristol-Myers Squibb Co and Otsuka Pharmaceutical Co Ltd announced two newly available...period of up to 26 weeks. Bristol-Myers Squibb and Otsuka Pharmaceutical are collaborative partners in the development...


Bristol-Myers Squibb and Otsuka Pharmaceutical Co, Ltd announce exclusive...: News wire article from: Chemical Business Newsbase December 27, 2006 700+ words
...Press Release) Bristol-Myers Squibb company and Otsuka Pharmaceutical Co, Ltd announced Otsuka...discovered by Bristol-Myers Squibb, is a dipeptidyl peptidase...by Otsuka to Bristol-Myers Squibb. Bristol-Myers Squibb...


Bristol-Myers Squibb and Otsuka Pharmaceutical Company Launch New Rapidly...: Press release article from: PR Newswire August 17, 2006 700+ words
...Bipolar I Disorder PRINCETON, N.J. and TOKYO, Aug. 17 /PRNewswire-FirstCall/ -- Bristol-Myers Squibb Company and Otsuka Pharmaceutical Co., Ltd. today announced the launch of ABILIFY(R) DISCMELT(TM) (aripiprazole) Orally...


Bristol-Myers Squibb granted Otsuka Pharmaceutical the exclusive rights in...: Magazine article from: Medical Marketing & Media February 1, 2007 700+ words
Bristol-Myers Squibb granted Otsuka Pharmaceutical the exclusive rights in Japan to develop and commercialize the investigational compound saxagliptin, which is being studied for...


Abilify approval.(RXs)(Bristol-Myers Squibb Co.)(Otsuka Pharmaceutical Company...: Magazine article from: Chain Drug Review January 22, 2007 700+ words
Bristol-Myers Squibb Co. and Otsuka Pharmaceutical Co. have debuted Abilify injection. The product is indicated for adults with agitation associated with schizophrenia or bipolar mania.


B-M S and Otsuka launch Abilify Discmelt.(Bristol-Myers Squibb and Otsuka...: Newspaper article from: Pharma Marketletter September 4, 2006 700+ words
US drugmaker Bristol-Myers Squibb and Japan's Otsuka Pharmaceutical have announced the launch of an orally disintegrating tablet version of their co-developed antipsychotic Abilify (arpiprazol...

For more facts and information, see all results

The AccessMyLibrary advertising network includes: